FDA grants designation as Breakthrough Device
28.11.2022
The FDA has granted PentraSorb CRP designation as a Breakthrough Device. A remarkable achievement.
Second part of the second episode of our podcast has been published on YouTube
19.05.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
This is the second part of the conversation between Henrike and Oliver
Second episode of our podcast has been published
08.04.2022
In the second episode Henrike has a chat with our colleague Oliver Wenske
German Journal "Ärzteblatt" on C-reactive protein
01.04.2022
Today the north-eastern German journal reports on C-reactive protein
Advanced training course on apheresis in acute COVID-19
06.04.2022
The event series of Brandenburg College For Nephrology starts of with the topic of CRP-Apheresis.
The first episode of our podcast with Pentracor CEO Dr. Sheriff is online!
12.02.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
The ÄrzteZeitung reports on successes with CRP apheresis in severe COVID-19 pneumonia
18.01.2022
The article states that selective CRP apheresis could be an effective therapy option for COVID-19 patients with respiratory failure and greatly increased CRP levels, and that initial data from the German registry CACOV are encouraging.
Rainer Mohr is the new CFO of Pentracor GmbH since the beginning of the year
Hennigsdorf, January 20, 2022 - The medical technology company Pentracor GmbH from Hennigsdorf (convertible bond ISIN: DE000A289XB9, WKN: A289XB) has employed Rainer Mohr as a new Chief Financial Officer (CFO) since January 1, 2022.
In this function, Rainer Mohr controls and implements the strategic development of the company in all commercial and financial areas in close coordination and cooperation with the management of Pentracor.
Pentracor CAMI-1 study praised as groundbreaking
11.01.2022
The authors of the review article “Immune Mechanisms of Plaque Instability” from the Charité Cardiology Department describe the Pentracor CAMI-1 study “CRP apheresis in Acute Myocardial Infarction” as groundbreaking.
